Search PubMed⌕ Search

PubMed · 8268140

Gangliosides can activate human alternative complement pathway.

Abstract

The alternative complement pathway (ACP) in vertebrates is known to be important in inflammatory reactions, and to be activated by foreign substances such as bacterial lipopolysaccharide (LPS) and zymosan, although to date no intrinsic activators have been identified except complement receptor type 2. From the point of the structural similarity of LPS to ganglioside, we have investigated gangliosides which are abundantly present in animal cells for their activity on the human ACP. All of seven gangliosides tested were found to activate this pathway in a manner depending on the number of sialic acids and neutral sugars contained in the molecules. A dose-response study suggested a correlation of the threshold in ganglioside concentration with its critical micelle concentration. Gangliosides may thus serve as an intrinsic activator for ACP in animals, thereby leading to inflammation. The possibility of the participation of sialidase in complement activation is also discussed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Oshima, G Soma, D Mizuno. 1993. Gangliosides can activate human alternative complement pathway.. https://doi.org/10.1093/intimm%2F5.10.1349

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The central role of the alternative complement pathway in human disease.

The complement system is increasingly recognized as important in the pathogenesis of tissue injury in vivo following immune, ischemic, or infectious insults. Within the complement system, three pathways are capable of initiating the processes that result in C3 activation: classical, alternative, and lectin. Although the roles that proinflammatory peptides and complexes generated during complement activation play in mediating disease processes have been studied extensively, the relative contributions of the three activating pathways is less well understood. Herein we examine recent evidence that the alternative complement pathway plays a key and, in most instances, obligate role in generating proinflammatory complement activation products in vivo. In addition, we discuss new concepts regarding the mechanisms by which the alternative pathway is activated in vivo, as recent clinical findings and experimental results have provided evidence that continuous active control of this pathway is necessary to prevent unintended targeting and injury to self tissues.

Complement Pathway, Alternative↗

Loin pain-hematuria syndrome with a distinctive vascular lesion and alternative pathway complement activation.

We describe a 48-year-old woman with loin pain-hematuria syndrome. Her renal abnormalities included conspicuous microaneurysmal and glomeruloid (plexiform) angiomatous changes. The deposition of both properdin and the C5b-9 complex, as well as the usual C3, in arterioles argues for complement activation. To our knowledge, neither of these features has been previously described. We speculate about the cause of loin pain-hematuria syndrome and note the uncommonness of this entity in the United States as opposed to Great Britain.

Complement Pathway, Alternative↗